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Abstract: In order to ascertain their external environment, cells and tissues have the capability
to sense and process a variety of stresses, including stretching and compression forces. These
mechanical forces, as experienced by cells and tissues, are then converted into biochemical signals
within the cell, leading to a number of cellular mechanisms being activated, including proliferation,
differentiation and migration. If the conversion of mechanical cues into biochemical signals is
perturbed in any way, then this can be potentially implicated in chronic disease development and
processes such as neurological disorders, cancer and obesity. This review will focus on how the
interplay between mechanotransduction, cellular structure, metabolism and signalling cascades led
by the Hippo-YAP/TAZ axis can lead to a number of chronic diseases and suggest how we can target
various pathways in order to design therapeutic targets for these debilitating diseases and conditions.
Keywords: Hippo; YAP; TAZ; polarity; cancer; mechanotransduction; obesity; aPKC; neurodegenerative
disease; talin; integrins
1. Mechanotransduction: Overview and Structural Basis
The ability of cells to detect and react to changes in their microenvironment is critical for the
maintenance of both cellular function and tissue homeostasis [1,2]. Recent studies have expanded our
understanding of a cell’s ability to sense its physical surroundings and respond to these stimuli to initiate
the activation of intracellular signalling pathways that trigger downstream events [1,3]. Indeed, living
cells are constantly in contact with mechanical cues and can translate the mechanical forces experienced
in their environment into biochemical and behavioral responses. Cells can react to these forces
through specific basal proteins and transduce this into a process known as mechanotransduction [2,4,5].
Mechanotransduction is a process initiated by mechanically induced changes in protein conformation
which result in cytoskeleton rearrangements, cell division control and differentiation. The mechanical
forces experienced by the cell are processed into biochemical signals to ultimately control gene
expression, cell shape and cell fate [6]. The cell’s response to mechanical cues within the environment
requires the cell’s ability to both transmit and generate forces. This occurs through basal interactions
with the cellular extracellular matrix (ECM) and cell-cell interactions with neighbouring cells through
specialized transmembrane proteins [1,2]. Mechanotransduction is crucial for many cellular functions
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such as cell adhesion, motility, migration, proliferation, differentiation and survival. If abnormalities in
mechanotransduction occur this can for example lead to aberrant cell behavior and activation of key
signalling pathways to drive phenotypical switching into more mesenchymal-like cancer cells from
normal cells [4,7].
Cells are physically connected to the ECM through the transmembrane receptors protein family
of integrins focal adhesion (FA-related proteins). External mechanical signals are sensed at FAs and
translated into biochemical information through integrin-related signalling pathways for maintaining
proper cellular functions in cell shape, migration and survival [8]. Integrin activation is required for
the normal functionality of cell adhesion, migration and extracellular matrix assembly. Integrins are
a family of heterodimeric proteins comprising alpha and beta subunits that are activated through
modulation of the cytoplasmic tail of integrin subunits and this activation is regulated by various
biochemical signalling pathways. Besides their requirement for normal cellular mechanosensing, tumor
cell migration, invasion, growth and metastasis are also regulated by abbrerant integrin-mediated
mechanical signals [9,10].
One of the most extensively studied set of oncogenes of recent times and a potent mechanosensor
in mammals are Yes-associated protein (YAP) and its homologous protein Transcriptional Co-Activator
With PDZ-Binding Motif (TAZ). YAP/TAZ are sensors of structural and mechanical features of the
cell microenvironment that are regulated by soluble extracellular factors, cell-to-cell adhesion and
mechanotransduction [11,12] and play a central role in delivering mechanical cues from surrounding
cells to the transcriptional machinery of the nucleus [13,14]. YAP and TAZ function as transcriptional
co-activators shuttling between the cytoplasm and nucleus to induce the expression of cell-proliferative
and anti-apoptotic genes by interacting with transcription factors, especially the TEA domain family
members (TEAD) [12]. Although YAP is cytoplasmic at high cell density, the loss of cell contact with
neighbouring cells or cell spreading results in YAP translocation to the nucleus. The expansion of cell
contacts spreading over their basal substrate, the strength of the substrate and resulting mechanical
tension are the key determinants of subcellular YAP localization in response to cell density [11,15,16].
Mechanotransduction affects YAP both independently of the canonical Hippo signalling pathway and
with the involvement of key Hippo signalling pathway kinases MST and LATS. Signalling cascades
downstream of integrins are known to regulate YAP and TAZ activation [17–19]. Most of the main
mechanosensitive phenotypes induced through YAP/TAZ lean on integrin-mediated adhesion [11].
YAP and TAZ can also be directly regulated by the extracellular matrix (ECM) stiffness and YAP itself
is involved in FA assembly [15,20,21] (Figure 1).
Mechanosensing the alterations of ECM stiffness can also be a causal input driving aberrant cell
behaviours. The stiffness of ECM is a universal mechanical cue which control’s the preference of a cell
between its choice of proliferation and death [16]. When cells perceive stiffness in the ECM, they
change their spread and migration potential accordingly. YAP/TAZ activity is also regulated in this
scenario. As mentioned, YAP and TAZ are activated by a stiff ECM and stretched cell shape in contrast
to inhibition by a soft ECM environment and round cell shape [11,14,16,22,23]. Cells cultured on highly
stiff ECM display activated YAP/TAZ with high nuclear localization and subsequent transcriptional
activity, whereas cells arrest when YAP/TAZ is inhibited and relocalised to the cytoplasm on a soft
ECM. In stiffer ECM, cells continue to proliferate and execute invasive phenotypes by increasing the
expression and activity of adhesion receptors and thereby mechanotransduction pathways [11,14–16].
Another key regulator of mechanotransduction in relation to its environment is cellular polarity, which
we will discuss in the next section.
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Figure 1. The regulation of YAP at the level of the extracellular matrix involves various proteins involved 
in stabilizing and activating YAP. Integrins sense the external forces and transmit this signal to talin 
family members which allow YAP and accessory proteins to act as mechanosensors within the cell. 
2. Mechanotranduction and Cell Polarity 
Cell polarization is an essential function of several cell types including epithelial cells and 
migratory cells. This part of the review will focus on the interplay between cell polarity and 
mechanical cues. Cell polarity can occur along several axes, including an anterio-posterior (A–P) axis 
(e.g., in migratory cells and neurons), and apicobasal and planar axes (e.g., in epithelia). In epithelia 
and other cell types, apico-basal polarity is the consequence of localization and activity of mutually 
antagonizing complexes, including the Par, Crumbs and Scribble complexes (for reviews see [24,25]). 
The Par proteins are segregated along the apico-basal axis in epithelia with an apical Par complex 
consisting of Par6/Par3/aPKC and a basolateral complex consisting of Par1/4/5. At the apical 
membrane aPKC activity functions to activate apical polarity substrates and restrict activity of 
basolateral proteins and conversely, Par-1 mediates kinase activity at the basolateral membrane 
where aPKC is excluded [26]. In the C. elegans zygote, a similar distribution of Par proteins is observed 
along an A/P axis. Here polarity is a result of mechanical cues exerted by cytoskeletal components. 
Indeed, the differential diffusion of Par proteins is a consequence of actomyosin contractions 
orchestrated by the oocyte maturation; coinciding with a cue originating from the centrosome, which 
causes a cortical flow [27,28]. This flow redistributes Par3 to the anterior side via a process called 
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2. Mechanotranduction a d Cell Polarity
Cell polarization is an essential function of several cell types including epithelial cells and migratory
cells. This part of the review will focus on the interplay between cell polarity and mechanical cues.
Cell polarity can occur along several axes, including an anterio-posterior (A–P) axis (e.g., in migratory
cells and neurons), and apicobasal and planar axes (e.g., in epithelia). In epithelia and other cell
types, apico-basal polarity is the consequence of localization and activity of mutually antagonizing
complex s, includ g the Par, Crumbs and Scribble complexes (for reviews see [24,25]). The Par
proteins are segregated along the apico-basal xis in epithelia w th an apic l Par compl x consisting
of Par6/Par3/aPKC and a basolateral complex consisting of Par1/4/5. At the apical membrane aPKC
activity functions to activate apical polarity substrates and restrict activity of basolateral proteins and
conversely, Par-1 mediates kinase activity at the basolateral membrane where aPKC is excluded [26].
In the C. elegans zygote, a similar distribution of Par proteins is observed along an A/P axis. Here
polarity is a result of mechanical cues exerted by cytoskeletal components. Indeed, the differential
diffusion of Par proteins is a consequence of actomyosin contr ctions orchestrated by the oocyte
maturation; coinciding with a cue originating from the centrosome, which causes a cortical flow [27,28].
This flow redistributes Par3 to the anterior side via a process called advection. The activity of the
redistributed Par proteins in this manner allows for chemical amplification of A/P identity and
polarization. Mechanical cues are sufficient for other cells to polarize along an axis as well. For example,
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in an attempt to find the minimal requirement for polarization of fibroblasts it was recently shown
that a single point of adhesion with an above-threshold force to a fibronectin coated bead is enough
to cause redistribution of the actomyosin structure and repositioning of the centrosome, supporting
polarized behaviour [29,30]. In migratory cells mechanical force also induces polarization by formation
of a single leading edge and suppressing of other protrusions by means of sensing membrane tension.
This has been elegantly shown in neutrophils, where a leading edge protrusion characterized by
increased membrane tension exerts long range inhibition on the rest of the cell, as measured by reduced
Rac activity and SCAR/WAVE complex formation. This long-range inhibition is purely the result
of a mechanical stimulus since application of membrane tension by applying a sucking force with
a micropipette at one end of the cell causes the described effects [31].
Polarity proteins have also been involved in mechanosensing and altering the mechanical
properties of cells. For example, aPKC activity has been linked to remodelling of the keratin
intermediate filament (KIF) network in lung epithelial cells upon shear stress by phosphorylation of
keratin at the phosphosite Ser-33, promoting its interaction with 14-3-3 [32]. Furthermore, aberrant
aPKC signalling is oncogenic and elevated expression levels of aPKC have been observed in several
cancers [33–36]. Besides loss of polarity, overexpression of aPKC in cancer has also been implicated in
altering the mechanical properties of cells. Indeed, spheroids consisting of MCF10A breast cancer cells
expressing aPKC have been observed to have increased surface tension [37]. Furthermore junctions
between aPKC expressing and non-aPKC expressing cells bear an increased tension that allow them to
actively extrude into the lamina [37].
Localization of polarity proteins also induces changes in local cytoskeletal composition.
For example, Rho-GTPases such as Cdc42 and Rac stimulate actin nucleators and suppress destabilizing
factors. Additionally, dynein pulling motors are regulated by the PAR polarity proteins in A/P polarized
cells, where inhibition occurs at the anterior pole, resulting in pulling of the mitotic spindle towards
the posterior pole [38,39]. Specifically aPKC has been implicated in phosphorylation of LIN5 inhibiting
microtubule pulling force [40].
Mechanical cues and polarity have also been interlinked in higher order morphogenesis.
For example in the C. elegans embryo, planar polarity of the apical Par module in the epidermis
is established through muscle contractions that are relayed to the epidermal tight junctions via integrins
and ECM components and hemidesmosomes [41]. Coupling of polarity to altering mechanistic
properties has also been observed in fly follicles, where egg chamber rotation and elongation are an
important part of maturation. Cetara and co-authors show in a recent paper that the elongation of the
egg chamber is dependent on the planar alignment of actin fibers at the basolateral membrane [42].
They further show that loss of egg rotation disturbs this planar alignment, likely due to the fact that
polarity information cannot be transmitted to the expanding epithelium surrounding the egg, but the
exact mechanism has not been elucidated.
Several polarity proteins also induce signalling to the Hippo pathway and YAP/TAZ itself. It has
been shown that the apical transmembrane protein Crumbs can associate with FERM domain-containing
protein 6 (FRMD6), Kibra and Merlin composing a scaffold that activates the Hippo pathway [43–45].
Furthermore YAP is also supressed by the tight junction binding protein AMOTS [46–48] and by
binding to α-catenin at adherens junctions [49,50].
In contrast, aPKC and the Par complex have been shown to drive nuclear YAP signalling.
In epithelial cells overexpression of activated aPKC causes loss of contact inhibition and overgrowth
by uncoupling MST1/2 from LATS1/2, causing nuclear accumulation of YAP. Additionally in MDCK
cells specifically, downregulation of AMOTS expression also caused a loss of YAP localization to
junctions and a spindle like phenotype [51]. Inactivation of the Hippo pathway has also been associated
with elevated expression of Par-3 in metastatic prostate cancer by driving a KIBRA/Par-3/aPKC
complex formation in lieu of the activating KIBRA/Merlin/FRMD6 complex [52]. Suppression of Hippo
signalling by polarity is also seen in the developing embryo, where an inner cell mass is non-polarized
and has a different fate then the surrounding trophectoderm which is polarized. This is achieved
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by polarity signals that inactivate Hippo signalling and cause translocation of YAP to the nucleus,
activating a TEAD-dependent transcriptional program (for a recent review see [53]). The Par complex
seems to be important for at the 32-cell stage of embryonic development, whereas at the 16-cell stage
Par-independent mechanisms are also involved [54].
There seems to be a reciprocal interplay between polarity and Hippo signalling since a recent
genetic screen looking for proteins in C. elegans that are involved in maintenance of cell polarity in the
growing intestine implicated several components of the Hippo pathway including YAP and TEAD [55].
It thus seems that the regulation of Hippo signalling by polarity is dependent on the order of
events during polarization, the different polarity complexes formed and thus the level and molecular
tuning of the respective proteins, a regulation which seems to include a feedback control from the
Hippo pathway itself. How these polarity cues are linked to mechanical signals that act on the Hippo
pathway needs to be elucidated further, but because of the close interplay between the two, some
cross-regulation is inevitable.
In conclusion it is emerging that mechanical stimuli and polarity are closely interlinked, both
at the level of individual cells as well as at the level of the developing tissue. While some systems
like the C. elegans zygote have been extensively studied, many of the mechanisms regarding coupling
of mechanical to chemical stimuli have yet to be resolved. Loss of polarisation can lead to cellular
transformation and epithelial to mesenchymal transition, a tumour-initiating process. The next section
will explore the link between mechanotransduction and disease.
3. Mechanotransduction Signalling in Disease
Mechanotransduction is an important cellular hallmark in the formation of chronic disease.
Loss of polarity or mechanosensing can lead to a range of diseases including cancer, obesity and
neurodegenerative diseases and various pathways can be involved in this process. Figure 2 provides
an overview of the types of signalling pathways involved in these diseases and we shall discuss this in
more detail in the coming section.
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3.1. Cancer
Solid tumors exhibit increased ECM stiffness and crosslinking that promote an invasive
phenotype in cancer cells. Increased stiffness of the ECM can also lead to a disruption of the
epithelial polarity resulting in migration and metastasis [4]. In addition, stiff ECM activates the
β1-integrin-FAK-Src-PI3K-PDK1 pathway to facilitate YAP nuclear translocation and transcriptional
activation as previously discussed [11,56,57]. Concomitantly, YAP/TAZ is overexpressed and highly
accumulated in the nuclei of cancer cells, initiating the transcription of YAP/TAZ target genes to drive
proliferation, invasion and metastasis [13]. Thus, YAP/TAZ plays a crucial role in driving tumorigenesis
as dysregulation of the Hippo pathway and sustained activation of YAP drives uncontrollable
growth [58]. There is scope for further investigations in the future of the role of novel ECM components
and how they relate to Hippo pathway signalling. We have already previously identified a family of
ECM cross-linkers (Enigma family members) which link the ECM to the cytoskeleton and result in the
regulation of YAP [16]. It has also been shown that the mechanical regulation of the Hippo pathway is
conserved in a wide range of species [59–61]. Mechanotransduction could play a potentially important
role in the development of targeted therapies targeting the cancer cell’s pro-proliferative and survival
signals stemming from its interaction with the stroma. An example of such a target could be the talin
family of proteins.
Extensive biological studies have hinted that the talin family of proteins may play an important role
in the transduction of the integrin signal. Talins are a major cytoskeletal protein at focal adhesions that
link intracellular networks with the ECM via its coupling with the actin cytoskeleton and membrane
integrins [9,10,62,63]. Talins are comprised of a globular head and a long rod domain. The FERM
domain within the talin head domain provides a binding site to the cytoplasmic integrin β subunit
whereas the C-terminal talin rod containing several vinculin binding sites provides a connection to the
actin cytoskeleton and the ECM within the cell suggesting that talin is an important mechanosensitive
molecule [2,64,65]. In vertebrates, there are two talin genes: talin1 and talin2. The talin1 protein was
found to regulate focal adhesion dynamics, cell migration and invasion; whereas the precise role of the
talin2 protein in cancer is not clear. Talin1 is expressed in nearly all tissues whereas talin2 is mainly
expressed in the heart, brain, testis and muscles [66]. Talin2 functions distinctly from talin1 in the
regulation of cell invasion and is usually localized at large focal adhesions and fibrillary adhesions.
In the absence of talin1, talin2 was found to regulate focal adhesion assembly and focal adhesion
kinase signalling [67]. Interestingly, the talin2 head domain (TH2) has a higher affinity and a much
stronger binding to β-integrin tails than talin1 head domain (TH1) which is important for traction force
generation and cell invasion (Figure 1). The strong binding of talin2 with the β-integrin tail produces
the aforementioned traction force which goes on to colocalise with invadopodia and encourages
invadopodium-mediated matrix degradation. This is a key mechanism for cancer cell invasion [67].
In breast cancer cell lines, talin2 controls production of traction force through its strong binding with
β-integrins thus leading to the regulation of various processes including cell migration, invasion,
tumor growth and metastasis and potentially oncogenic activation of various proteins [10]. The talin
family has also been linked to obesity since talin levels increase with increasing adipose cell size in
the growing fat pad. The next section further explores the link between mechanotransduction and
adipose regulation.
3.2. Obesity
In addition to chemical and hormonal influences, mechanotransduction signals play an important
role in adipogenesis. These mechanical cues as well as having an important role in adipocyte
development, also play a major role in differentiation to adipogenic lineages [68]. A combination of all
of these influences, in addition to distinct precursor populations of adipocytes, together with final
tissue location influencing functionality, results in specific depot physiology for the prevailing adipose
tissue mass formed [69,70].
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The number of adipocyte cells in human adults appear to be relatively fixed, even after weight
loss, with large variations in cell size both within and between individuals. A stable number of cells
and an approximate 10% turnover annually, which is not influenced by energy balance, indicates
a tight regulatory control of the accumulated tissue mass formed [71,72]. This is of importance in the
context of obesity and the resulting pathology caused by dysregulation of whole body metabolism
and insulin resistance. The physiological response to excess calorie intake is adipocyte lipid loading,
causing an increased cell volume. This propagates the metabolic complications of obesity. Indeed,
enhanced accumulation of lipid may lead to adipocyte hypertrophy, characteristic of adipose tissue
dysfunction [73].
Adipocytes store lipids in the form of triacylglycerides in a single, large unilocular lipid filled
droplet. The consequence of this is an increase in the stiffness of the adipocyte [74]. This stiffness adds
to mechanical stress such as different loading or weight bearing strains which also generate forces which
adipocytes are exposed to. The resultant mechanical forces can be transduced to affect adipogenesis [75].
These forces are transduced by various protein complexes such as: focal adhesions interconnecting
with the actin cytoskeleton [76] or ion channels that are sensitive to mechanical stress [77]. In line with
this, a recent study has identified a volume sensitive ion channel on the adipocyte surface which can
regulate insulin signalling [78]. This protein, SWELL1, is increased in human hypertrophic adipocytes
of obese humans and is required for glucose uptake via PI3K-AKT2-GLUT4 signalling activity. This
provides evidence of a link between mechanoreception and insulin signalling which is activated under
obesogenic conditions. Following transduction, static or dynamic forces which alter adipocyte cell
shape or the adipocyte microenvironment have been shown to activate various intracellular pathways
including RhoA/ROCK, Akt/Erk and the Hippo pathway which influence gene expression and cell
fate [79].
Chronic mechanical force such as that exerted through extracellular matrix stiffness, as occurs
through the development of adipose tissue fibrosis, has been associated with metabolic complications
in obesity. Evidence for this has been provided through the preparation of 3D adipocyte hydrogel
cultures with incorporated decellularized material from the adipose tissue of obese subjects. This
induced dysfunctional adipocyte metabolism and increased expression of connective tissue growth
factor (CTGF) through the Hippo related YAP/TEAD-dependent pathway [80].
A cells metabolic status plays an important role in regulating key members of the Hippo pathway,
YAP and TAZ. These factors have both been shown to regulate and be regulated by multiple metabolic
pathways and energy-sensing pathways such as via AMP-activated protein kinase (AMPK) [81–84].
The master regulator of metabolism and proliferation, c-Myc, which itself is influenced by growth
factor and nutrient availability, has been shown to be influenced by components of the Hippo
pathway [85]. It has been shown that adipocyte proliferation may be activated by the SIRT1/c-Myc
pathway. Reduced levels of SIRT1 resulted in hyperacetylated c-Myc which promoted the formation of
a metabolically dysfunctional 3T3-L1 preadipocyte phenotype [86]. Within adipocytes, the activity
of one of the key transcriptional factors for adipogenesis, PPARy is suppressed by TAZ. In this
regard, adipose-specific TAZ knockout mice show improvements in insulin sensitivity and glucose
metabolism, establishing a potential role for TAZ in promoting insulin resistance [87]. Liraglutide,
a GLP-1 analogue and antidiabetic agent also used to treat obesity, has shown to activate the Hippo
pathway by increasing YAP related pathway components (MST1, LATS1 and p-YAP). This results in
reduced cell proliferation but increased cell differentiation of 3T3-L1 preadipocytes [88]. These studies
suggest crucial connections with the regulation of substrate metabolism and the Hippo pathway. It is
therefore key to establish the mechanisms for cross-talk between mechanotransduction pathways such
as the Hippo pathway and substrate metabolism, tissue expansion, the development of adipocyte
hypertrophy and insulin resistance.
Obesity is a risk factor for cancer development, and a recent research focus has provided evidence
that this link may be partially due to alterations in the Hippo pathway. Of interest is that adipocytes
form a major component of the tumour microenvironment in for example breast, colon and gastric
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cancers and can therefore directly contribute to cancer cell development [89,90]. Obesity has been
shown to accelerate cancer development following the subcutaneous injection of murine forestomach
carcinoma cells. This was shown to act through the influence of the adipokine visfatin whose
concentration in serum was correlated with SIRT1 (a multifunctional protein that regulates metabolic
activity). The upregulated SIRT1 promoted YAP2/TEAD4 activation and the development of cancer
in a diet-induced murine obesity model [91]. Obesity and insulin resistance are also important risk
factors for the development of endometrial cancer where knockdown of YAP/TAZ has been shown to
inhibit insulin signalling via phosphorylation of IRS1/2, a mediator of insulin and IGF-1 signalling
in endometrial cell lines [92]. The Hippo pathway may therefore represent a novel target for cancer
prevention where adipocytes are closely associated with cancer such as breast cancer [93,94] or where
insulin resistance is associated with cancer progression [95].
One strategy for treating obesity has been through inducing a switch from white to brown like
(beige) adipocytes, which can arise postnatally in white adipose tissue depots. Beige adipocytes,
which dissipate energy as heat as opposed to storing fat, can be induced by various cues including
temperature, exercise, adrenergic stimulation, nutritional and hormonal signals [96]. These adipocytes
are associated with increased energy expenditure and improved insulin sensitivity, similar to brown
adipocytes. Understanding how beige selective pathways are induced can provide new insights that
could allow for the targeted selection of this metabolically favorable phenotype of adipocyte. Although
developmentally of different origin (muscle-like), YAP/TAZ signalling has also been shown to regulate
insulin signalling in muscle where TAZ has shown to stimulate insulin sensitivity by upregulating
IRS1 which mediates GLUT4 uptake of glucose in muscle cells [97]. Brown adipocytes (BAT) are
functionally similar to beige adipocytes. Both cell types show multilocular deposition of lipid and
increased oxidative metabolism through upregulation of UCP1, which induces thermogenesis. It is
therefore of interest that BAT development is dependent on YAP/TAZ signalling which upregulates
UCP1 expression and that this process is mediated through a cytoskeletal mechanotransduction
response [98].
Understanding the role of adipocytes in the context of obesity related disease processes, including
cancer, and uncovering tissue-specific molecules related to the functioning of the Hippo pathway
could provide biomarkers or targets for therapy. However, the association of the Hippo pathway with
multiple functions associated with growth and development in tissues also provides a challenge with
respect to potential side effects.
3.3. Neurodegenerative Disease
The sensory processes of hearing, touch, and pain sensation depend on transducing certain
types of mechanical force into sensory information. Sensory disorders involving dysfunction of these
processes have been identified (such as deafness) [99]. However, additionally, sensing and transduction
of other local tissue mechanical forces are critical for normal neuronal development, homeostasis, and
function. In the developing embryonic nervous system, neuronal progenitors migrate, and neuronal
axons extend, branch, and find their synaptic targets through various embryonic tissue types [100].
In normal adult function, neurons are also under constantly changing mechanical forces due to the
movement or pressure of surrounding muscles or tissues, especially during tissue damage. Stretching
of neurons, such as during regenerative axon growth, is known to promote neurite outgrowth and to
be a potent regulator of axon growth.
Much is now known of the general molecular and biochemical pathways governing neuronal
development, function and disease. However, the specific roles of mechanical forces in neuronal
homeostasis and function have only recently started to be determined. For example, retinal ganglion
axons prefer to grow through ‘softer’ tissue and avoid ‘stiffer’ tissue in Xenopus brains [101]. A wide
variety of proteins with links to mechanotransduction have been identified as important to neuronal
development and function/homeostasis, including mechanosensitive Piezo ion channels (e.g., Piezo-1,
Piezo-2), transient potential receptor (TRP) channels (e.g., TRPV2, TRPV4), transmembrane or
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extracellular matrix (ECM) proteins (e.g., integrins, β-spectrin), and intracellular signalling proteins
(e.g., YAP/TAZ).
Despite this, even less is known of the importance or role of mechanotransduction in the
development or progression of neurodegenerative diseases (NDD). Changes in the ECM and/or tissue
stiffness have been reported in traumatic brain injury and brain cancer [102] and in central nervous
system glial scars in rats [103] but also in Alzheimer’s disease [104,105], Parkinson’s disease [106],
and multiple sclerosis [107], suggesting that stiffness changes may be relevant to NDD. Several
recent studies have provided intriguing evidence that mechanotransduction proteins may also have
fundamental direct roles in neurodegenerative disease.
Piezo-1 is a mechanically gated calcium channel mainly expressed on the cell membrane
of myelinated neurons and, as it responds to mechanical stimuli, it plays an important role in
mechanotransduction [108]. On activation by traction forces, Piezo-1 allows the entrance of calcium
ions (Ca2+) into the cell. Activation of Piezo-1 in neuronal stem cells induces their differentiation into
neurons, rather than astrocytes [109]. Furthermore, Piezo-1 activation results in the nuclear targeting of
YAP and TAZ, an event implicated in the myelin formation in the central nervous system (CNS) [109].
Disorders involving progressive demyelination (loss of myelin), called demyelinating disorders can
lead to axonal injury, neurodegeneration, and significant disability and death [110,111]. Demyelinating
disorders are often characterised by an axonal Ca2+ imbalance, resulting in an increased influx of Ca2+,
thus causing elevated production of reactive oxygen species and excitotoxicity [112].
In a recent study, enhancing Piezo-1 activation with a small-molecule agonist Yoda-1 caused
axon demyelination in mouse cerebellar slices, while a pharmacological Piezo-1 inhibitor, GsMTx4,
caused increased myelin formation [108]. It was hypothesised that over-activation of Piezo-1 induces
increased influx of Ca2+ into CNS axons, release of Ca2+ from intracellular stores, and activation of
calpain, a protease that can cleave talin and modify integrin-mediated cell adhesion [108]. For this
reason, blocking Ca2+ influx by inhibition of the Piezo-1 Ca2+ channel might have therapeutic
implications in demyelinating and neurodegenerative disorders. Furthermore, GsMTx4 attenuated
axonal damage induced by demyelination and reduced microglial reactivity following activation
by LPS (lipopolysaccharide) [108]. Piezo-1 expression in amyloid plaque-reactive astrocytes is also
upregulated by peripheral bacterial infection in rats [113]. As microglial reactivity and/or other immune
mechanisms are thought to facilitate neurodegeneration, and are implicated in Alzheimer’s disease
progression, this further suggests the potential beneficial use of Piezo-1-modulating agents in treating
neurodegenerative disease.
Further evidence of mechanotransduction changes in neurodegeneration disease through the
YAP/Hippo pathway has recently been provided. Alexander disease (AxD) is a rare neurodegenerative
disease of primary astrocyte dysfunction which features gain-of-function mutations in and protein
aggregations of the astrocytic protein GFAP [114]. A Drosophila AxD model overexpressing a human
mutant form of GFAP (GFAPR79H) showed activation of the YAP/Hippo pathway, with resulting
abnormal changes to mechanotransduction proteins including lamin, focal adhesion kinase (FAK) and
ECM proteins, leading to behavioural abnormalities and neurodegeneration in this fly model [114].
Furthermore, brains of transgenic AxD mice showed increased tissue stiffness and iPSC-derived
astrocytes from one AxD patient displayed increased A-type lamin and nuclear-localised YAP compared
to control astrocytes [114]. Interestingly, a neuronal-specific isoform of YAP, YAPdeltaC, protects against
neuronal apoptosis in a model of the neurodegenerative disease Huntington’s disease (HD), by blocking
interaction of full-length YAP with p73 [115], and was recently shown to modulate neurodegeneration
in a mouse model of spinocerebellar ataxia 1 [116]. Additionally, activation of MST1 is increased
in human post-mortem HD cortex, and nuclear localisation of YAP is correspondingly decreased
in human HD cortex and in neuronal stem cells derived from HD patients (117), leading to altered
Hippo pathway gene expression [117]. The YAP/TAZ/Hippo pathway may therefore be a relevant
mechanism in mammalian neurodegenerative processes, and perhaps particularly in aggregation-prone
neurodegenerative diseases.
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Finally, glaucoma is an ocular disease featuring increased intraocular pressure (IOP), which
when untreated leads to retinal damage, the irreversible degeneration of retinal ganglion cell (RGC)
neurons, and blindness [118]. A number of mechanotransduction mechanisms and proteins have been
implicated in the various anatomical and physiological changes in the eye which lead to glaucoma
and, as a secondary consequence, RGC degeneration. Interestingly, however, the mechanosensitive
ion channels TRPV4 and TREK-1, as well as integrins, have been suggested to be directly involved
within RGC in pressure-induced dendritic retraction and RGC loss, in glaucoma [119], through sensing
stretch, compression, tension and/or shear of retinal or retinal-associated ocular components. TRPV4
is strongly expressed in RGCs, and induction of TRPV4 causes RGC degeneration and other related
ocular pathologies in mice and in vitro [119]. As mice with ablated TRPV4 or TREK genes show
reduced and increased sensitivity to mechanical stress, respectively [120,121], these channels may act
in opposition to regulate homeostatic responses to mechanical stress in the retina. Interestingly, TRPV4
activation causes YAP/TAZ nuclear translocation during cellular epithelial-mesenchymal transition
(EMT) in keratinocytes [122,123]. It will be useful to identify if TRPV4 also effects this process in retinal
ganglion cells. Further, aging is a risk factor for glaucoma, as well as other NDD. Many components of
the eye undergo tissue stiffening and ECM remodelling in older age [124]. Age-related changes in
tissue stiffness may be a relevant avenue for further investigation in NDD development.
In summary, the large number of mechanosensing proteins that have critical roles in neural
development and function/maintenance suggests that further roles for these proteins in NDD will
likely be discovered.
4. Conclusions
As we have conveyed, mechanotransduction plays a huge role in a wide range of cellular and
physiological processes of which the dysregulation can contribute to a number of chronic diseases
including obesity, diabetes, cancer (including loss of polarity/tissue context) and neurodegenerative
disease. Table 1 summarises the key pathways shown in this review, important proteins from these
pathways and how these proteins are implicated in a number of diseases.
Table 1. Proteins discussed in this review involved in mechanotransduction and diseases associated
with their dysfunction.
Pathway Protein Disease References
Extracellular matrix
(ECM)
Integrins Cancer [9,10]
Talin2 Cancer [10,66]
Hippo signalling
YAP
Alexander disease [114]
Huntington’s disease [115]
Spinocerebellar ataxia 1 [116]
Demyelinating disorders [109]
Cancer [4]
TAZ
Cancer [13]
Demyelinating disorders [109]
Type 2 diabetes [87]
Ion channels Piezo-1
Demyelinating disorders [108]
Alzheimer’s disease [113]
TRPV4 Glaucoma [119]
Polarity aPKC Cancer (contributing) [37]
Metabolic pathways UCP1 Obesity [98]
IRS1 Cancer [92]
Many of these signalling pathways involved in the process of mechanotransduction (and thus
tissue stiffness) seems to revolve around YAP/TAZ signalling. If YAP/TAZ which are established
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mechanosensors can be inhibited by therapy then we can potentially affect the levels of chronic disease
and tissue stiffening with increasing age.
Future therapeutic options for targeting tissue stiffness will include targeting the Hippo pathway.
As shown in Figure 3, if therapy is initiated during increasing tissue stiffness hypothetically we
can reduce the incidence of the chronic disease. The interplay between mechanotransduction and
chronic disease is a large field which we can explore with various targeted therapies with the ultimate
goal of treating cases of chronic disease.
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